Tressie Herrmann
Tressie Herrmann is an expert in Oncology at Centre Jean Perrin (France). Tressie Herrmann has authored 6 publications, the most recent in 2023, and is an investigator in 1 clinical trial, 1 of them ongoing. SLR score: 30 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties:
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2020 - 2023
Number : 6
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab. PMID 37288137 — neoplasms, drug therapy, immunotherapy, precision medicine, therapeutics, endometrial neoplasms, chemotherapy, msi-h | Onco Targets Ther | 2023 | 7 |
| Interdisciplinary Management for the First Patient With Post-COVID Double-Lung Transplantation in Inpatient Rehabilitation in the United States: A Case Report. PMID 35648112 — lung, rehabilitation, transplants, therapeutics, lung transplantation, transplantation, physical therapy modalities | Phys Ther | 2022 | 2 |
| Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study. PMID 34405573 — cells, retrospective studies, neoplasms, eosinophils, carcinoma, renal cell, immunotherapy, nivolumab, therapeutics, prognosis | Cancer Med | 2021 | 20 |
| Body Mass Index, Sarcopenia, and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma. PMID 34999587 — cells, body mass index, weight gain, carcinoma, renal cell, nivolumab, therapeutics, sarcopenia | Oncology | 2021 | 20 |
| Mutation of Tp53 in a Patient with Aggressive Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma OpenAlex W3177797409 — solitary fibrous tumors, neoplasms, central nervous system, genes, p53, therapeutics, nervous system, hemangiopericytoma, mutation | HAL (Le Centre pour la Communication Scientifique Directe) | 2020 | 0 |
Clinical Studies 1
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium PSMA 617 (Lu PSMA) Treatment for Castration resistant Metastatic Prostate Cancer NCT06600802 — genes, blood, blood specimen collection, neoplasms, prostate, biomarkers, prostatic neoplasms, castration, therapeutics, tissues, dna, men | N/A | Recruiting | 2024 |
LeadR Networks
Main global connection map